In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...
A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback